An early stage biopharmaceutical company is advancing innovative medicines for neurodegenerative diseases, starting with Amyotrophic Lateral Sclerosis, through a first-in-class gene therapy that enhances critical neurotrophic factor levels. The approach focuses on accelerated approvals and aims to address significant unmet clinical needs in various nerve disorders.